Additionally, a minor expansion of GZMB+ early-activation CD8 T cells was observed among responders, consistent with previous findings where baseline abundance and post-therapy expansion of PD1 + CD8 T cells were identified as predictors of ICI response in various cancer types11–13. This evidence concerns the gene CD8A and cancer.